CL2019001343A1 - Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. (divisional solicitud 201803065) - Google Patents
Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. (divisional solicitud 201803065)Info
- Publication number
- CL2019001343A1 CL2019001343A1 CL2019001343A CL2019001343A CL2019001343A1 CL 2019001343 A1 CL2019001343 A1 CL 2019001343A1 CL 2019001343 A CL2019001343 A CL 2019001343A CL 2019001343 A CL2019001343 A CL 2019001343A CL 2019001343 A1 CL2019001343 A1 CL 2019001343A1
- Authority
- CL
- Chile
- Prior art keywords
- wnt
- diseases
- signaling
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE DIVULGAN COMPUESTOS DE ISOQUINOLINA PARA EL TRATAMIENTO DE DIVERSAS ENFERMEDADES Y PATOLOGÍAS. MÁS CONCRETAMENTE, LA PRESENTE INVENCIÓN SE REFIERE AL USO DE UN COMPUESTO DE ISOQUINOLINA, O ANÁLOGOS DE LA MISMA, EN EL TRATAMIENTO DE TRASTORNOS CARACTERIZADOS POR LA ACTIVACIÓN DE LA SEÑALIZACIÓN DE LA VÍA WNT (POR EJEMPLO, CÁNCER, PROLIFERACIÓN CELULAR ANORMAL, ANGIOGÉNESIS, TRASTORNOS FIBRÓTICOS, ENFERMEDADES DEL CARTÍLAGO Y DEL HUESO, Y ARTROSIS), LA MODULACIÓN DE LOS EVENTOS CELULARES MEDIADOS POR LA SEÑALIZACIÓN DE LA VÍA WNT, ASÍ COMO ENFERMEDADES GENÉTICAS Y AFECCIONES/TRASTORNOS/ENFERMEDADES NEUROLÓGICOS DEBIDOS A MUTACIONES O A LA MALA REGULACIÓN DE LA VÍA WNT Y/O DE UNO O MÁS DE LOS COMPONENTES DE SEÑALIZACIÓN WNT. TAMBIÉN SE PROPORCIONAN MÉTODOS PARA TRATAR ESTADOS PATOLÓGICOS RELACIONADOS CON WNT.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662328255P | 2016-04-27 | 2016-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001343A1 true CL2019001343A1 (es) | 2019-10-11 |
Family
ID=60157337
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018003065A CL2018003065A1 (es) | 2016-04-27 | 2018-10-26 | Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. |
CL2019001343A CL2019001343A1 (es) | 2016-04-27 | 2019-05-16 | Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. (divisional solicitud 201803065) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018003065A CL2018003065A1 (es) | 2016-04-27 | 2018-10-26 | Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. |
Country Status (28)
Country | Link |
---|---|
US (7) | US10106527B2 (es) |
EP (2) | EP3892276A1 (es) |
JP (1) | JP6993985B2 (es) |
KR (1) | KR102374844B1 (es) |
CN (1) | CN109310690B (es) |
AR (1) | AR108325A1 (es) |
AU (1) | AU2017258193B2 (es) |
CA (1) | CA3022002A1 (es) |
CL (2) | CL2018003065A1 (es) |
CO (1) | CO2018012299A2 (es) |
CY (1) | CY1124302T1 (es) |
DK (1) | DK3448386T3 (es) |
ES (1) | ES2865374T3 (es) |
HR (1) | HRP20210607T1 (es) |
HU (1) | HUE054103T2 (es) |
IL (1) | IL262470B (es) |
LT (1) | LT3448386T (es) |
MA (1) | MA43619B1 (es) |
MD (1) | MD3448386T2 (es) |
MX (1) | MX2018013174A (es) |
PE (1) | PE20190326A1 (es) |
PH (1) | PH12018502258A1 (es) |
PL (1) | PL3448386T3 (es) |
PT (1) | PT3448386T (es) |
RS (1) | RS61879B1 (es) |
SG (2) | SG10201914054SA (es) |
SI (1) | SI3448386T1 (es) |
WO (1) | WO2017189829A1 (es) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975068B2 (en) | 2016-04-27 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl thiazoles as modulators of RORγT |
US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
CN113717154A (zh) | 2015-12-10 | 2021-11-30 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
AR108325A1 (es) * | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
CN109476660B (zh) | 2016-06-01 | 2023-04-04 | 拜斯丽治疗有限公司 | N-(5-(3-(7-(3-氟苯基)-3h-咪唑并[4,5-c]吡啶-2-基)-1h-吲唑-5-基)吡啶-3-基)-3-甲基丁酰胺的制备方法 |
KR20190135029A (ko) | 2017-03-30 | 2019-12-05 | 에프. 호프만-라 로슈 아게 | Hpk1의 억제제인 이소퀴놀린 |
WO2018226622A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
US10604514B2 (en) * | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
US10413537B2 (en) | 2017-10-27 | 2019-09-17 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof |
US10703748B2 (en) * | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
WO2019243999A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
CA3103976A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
WO2020150552A2 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
WO2021007378A1 (en) * | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
WO2021235293A1 (ja) * | 2020-05-20 | 2021-11-25 | 国立大学法人大阪大学 | Cugリピート配列の結合剤 |
CN117088878A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
KR101204247B1 (ko) | 2003-07-22 | 2012-11-22 | 아스텍스 테라퓨틱스 리미티드 | 3,4-이치환된 1h-피라졸 화합물 및 그의 시클린 의존성키나제 (cdk) 및 글리코겐 합성효소 키나제-3(gsk-3) 조정제로서 용도 |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
CA2594963A1 (en) | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
WO2007125405A2 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
NZ583351A (en) | 2007-08-15 | 2012-05-25 | Cytokinetics Inc | Modulate smooth muscle myosin and/or non-muscle myosin |
WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
JP2013501792A (ja) | 2009-08-10 | 2013-01-17 | サミュメッド リミテッド ライアビリティ カンパニー | Wnt/b−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用 |
DK2987487T3 (da) | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
US7998878B2 (en) | 2009-11-20 | 2011-08-16 | Eastman Kodak Company | Method for selective deposition and devices |
CA2986631C (en) | 2009-12-21 | 2020-06-02 | Samumed, Llc | 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof |
WO2011121555A1 (en) | 2010-03-31 | 2011-10-06 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
WO2012080284A2 (en) * | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
BR112014006127A2 (pt) | 2011-09-14 | 2017-04-04 | Samumed Llc | indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização wnt/b-catenina |
WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
WO2015143380A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
EP4086257A1 (en) | 2016-09-30 | 2022-11-09 | SRI International | Dual clk/cdk1 inhibitors for cancer treatment |
EP3813826A4 (en) | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR |
WO2020150545A1 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway |
-
2017
- 2017-04-26 AR ARP170101055A patent/AR108325A1/es unknown
- 2017-04-27 PE PE2018002194A patent/PE20190326A1/es unknown
- 2017-04-27 LT LTEP17790416.6T patent/LT3448386T/lt unknown
- 2017-04-27 ES ES17790416T patent/ES2865374T3/es active Active
- 2017-04-27 PT PT177904166T patent/PT3448386T/pt unknown
- 2017-04-27 SG SG10201914054SA patent/SG10201914054SA/en unknown
- 2017-04-27 JP JP2018556902A patent/JP6993985B2/ja active Active
- 2017-04-27 KR KR1020187034084A patent/KR102374844B1/ko active IP Right Grant
- 2017-04-27 CA CA3022002A patent/CA3022002A1/en active Pending
- 2017-04-27 HU HUE17790416A patent/HUE054103T2/hu unknown
- 2017-04-27 SG SG11201809301YA patent/SG11201809301YA/en unknown
- 2017-04-27 WO PCT/US2017/029805 patent/WO2017189829A1/en active Application Filing
- 2017-04-27 MD MDE20190282T patent/MD3448386T2/ro unknown
- 2017-04-27 MX MX2018013174A patent/MX2018013174A/es unknown
- 2017-04-27 CN CN201780037225.6A patent/CN109310690B/zh active Active
- 2017-04-27 RS RS20210466A patent/RS61879B1/sr unknown
- 2017-04-27 EP EP21159576.4A patent/EP3892276A1/en active Pending
- 2017-04-27 US US15/499,013 patent/US10106527B2/en active Active
- 2017-04-27 DK DK17790416.6T patent/DK3448386T3/da active
- 2017-04-27 PL PL17790416T patent/PL3448386T3/pl unknown
- 2017-04-27 EP EP17790416.6A patent/EP3448386B1/en active Active
- 2017-04-27 AU AU2017258193A patent/AU2017258193B2/en active Active
- 2017-04-27 SI SI201730725T patent/SI3448386T1/sl unknown
- 2017-04-27 MA MA43619A patent/MA43619B1/fr unknown
- 2017-12-06 US US15/833,917 patent/US9951048B1/en active Active
-
2018
- 2018-01-30 US US15/884,112 patent/US10100038B2/en active Active
- 2018-09-13 US US16/130,842 patent/US10544128B2/en active Active
- 2018-10-18 IL IL262470A patent/IL262470B/en unknown
- 2018-10-23 PH PH12018502258A patent/PH12018502258A1/en unknown
- 2018-10-26 CL CL2018003065A patent/CL2018003065A1/es unknown
- 2018-11-14 CO CONC2018/0012299A patent/CO2018012299A2/es unknown
-
2019
- 2019-05-16 CL CL2019001343A patent/CL2019001343A1/es unknown
- 2019-12-04 US US16/703,321 patent/US10947217B2/en active Active
-
2021
- 2021-01-22 US US17/155,577 patent/US11548872B2/en active Active
- 2021-04-16 HR HRP20210607TT patent/HRP20210607T1/hr unknown
- 2021-04-21 CY CY20211100344T patent/CY1124302T1/el unknown
-
2022
- 2022-11-18 US US17/990,133 patent/US20230286945A1/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975068B2 (en) | 2016-04-27 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl thiazoles as modulators of RORγT |
US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001343A1 (es) | Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. (divisional solicitud 201803065) | |
CO2018012655A2 (es) | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas | |
PH12016501835A1 (en) | 5-substituted indazole -3- carboxamides and preparation and use thereof | |
CY1122795T1 (el) | Ινδαζολο-3-καρβοξαμιδια και η χρηση τους ως αναστολεις του σηματοδοτικου μονοπατιου wnt/b-κατενινης | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
CL2019001626A1 (es) | Inhibidores de pequeñas moléculas de la familia jak de quinasas. | |
ECSP11011067A (es) | Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos | |
EA201590850A1 (ru) | Трициклические конденсированные производные тиофена как ингибиторы jak | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
PH12014502183A1 (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
CO6592044A2 (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedadese inmunes | |
UY39413A (es) | Compuestos inhibidores de metaloenzimas | |
AR111840A1 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales | |
CR20110351A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes | |
CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
EA201691141A1 (ru) | Соединения против ccr6 | |
CL2020002177A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas | |
CL2016002368A1 (es) | Compuestos derivados de benzamida, inhibidores de las vías de señalización de wnt; compuestos intermediarios; composiciones y combinaciones farmacológicas; útiles para la prevención o tratamiento de poliposis coli, síndrome de osteoporosispseudoglioma, vitreorretinopatía exudativa, angiogénesis retinal, enfermedad coronaria temprana, síndrome tetra amelia, diabetes mellitus tipo 2, síndrome de frágil, tumores sólidos, entre otras. |